In-vitro diagnostic tests

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2022. The most significant changes concern introducing and updating multiple EBM codes for IVD tests and adjusting tariffs and content of radiotherapy services.

In June 2022, NHS England and NHS Improvement (NHSEI) defined timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23. Applications can be submitted at any time throughout the year. Applications submitted before August 31, 2022, will be reviewed and considered for inclusion in the April 2023 update to the Test Directory

On June 06, 2022, the Reimbursement Commission of the Social Security Institution (SSI) released an updated version of the Healthcare Implementation Communique (SUT). The main changes relate to the increase in reimbursement fees of genetic tests by approximately 10%. Also, 138 new IVD tests have been added to the SUT.

In June 2022, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 0184 and 0081 with changes to be implemented no later than August 09, 2022. Two new procedure codes for robotic surgery and two new diagnostic codes were introduced.

In mid-June, the Swiss Federal Office for Public Health announced the update of the Annexes of the Services Ordinance (KLV/OPre). Annexes 1, 2, and 3 were updated. The updates related to the endocrine, IVD, and interventional radiology technology groups.

On June 7, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the overview of the 32 innovative healthcare research projects that will be funded, including those belonging to the eHealth technology group.

In late May 2022, the Norwegian Directorate of e-Health released an updated version of the National Laboratory code (NLK) system to be implemented no later than July 01, 2022, and associated tariffs for state and private laboratories to be implemented no later than June 01, 2022. NLK system is used for activity-based reimbursement by the Norwegian Health Economics Administration (Helfo) in outpatient settings.

On June 7, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the overview of the 32 innovative healthcare research projects that will be funded. The projects concerning the technologies belonging to eHealth, obstetrics and gynecology, pulmonary and airways, orthopedics, and other technology groups received funding.

On May 30, 2022, NHS England and NHS Improvement updated the 2021/22 National Genomic Test Directory for cancer (version 4), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. However, no new codes were introduced.

In May 2022, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (endoanchoring systems in endovascular aortic aneurysm repair, supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis, personalized external aortic root support using mesh in people with Marfan syndrome), one Medical Technologies Guidance (Sleepio to treat insomnia and insomnia symptoms), and six Medtech innovation Briefings (ViewSite Brain Access System, Granulox for managing chronic wounds, AMBLor for identifying melanomas, Bladder EpiCheck for detecting bladder cancer recurrence, and others). No MedTech-related clinical guidelines were published.

In April 2022, NHS England and NHS Improvement (NHSEI) announced that the timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23 are currently under review. Previously, NHSEI planned to publish and implement the 2022/23 Test Directory by April 2022. While the timelines are not confirmed, applications can still be submitted.

On April 21, 2022, NHS England and NHS Improvement updated the 2021/22 National Genomic Test Directory (version 3), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Forty-two new codes (test-indication combinations) were introduced in the cancer field, and fourteen for rare and inherited diseases.